| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2017072020 |
| Title |
Heteroarylcarboxamide Derivatives As Plasma Kallikrein Inhibitors. |
| Abstract |
The present invention relates to compounds of general formula I, wherein D1 to D3, A, R1, R2, Y and n are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema. |
| Applicant(s) |
Boehringer Ingelheim International Gmbh |
| Representative Drug(s) |
D0QH9W |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2015112081 |
| Title |
Benzoxazinone Derivatives for Treatment of Skin Diseases. |
| Abstract |
The present invention relates to methods and compositions for inhibiting the activity of skin proteases, especially human kallikrein 7 (KLK7), human kallikrein 5 (KLK5), and human kallikrein 14 (KLK14). More specifically, the invention relates to the use of substituted 3,1 -benzoxazin-4-ones being selective inhibitors of human skin kallikreins for the treatment of skin diseases, more specifically for the treatment of inflammatory skins diseases, especially Netherton syndrome. |
| Applicant(s) |
Sixera Pharma Ab |
| Representative Drug(s) |
D02MGJ |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013111108 |
| Title |
5-Membered Heteroarylcarboxamide Derivatives As Plasma Kallikrein Inhibitors. |
| Abstract |
The invention relates to a compound of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. |
| Applicant(s) |
Novartis Ag |
| Representative Drug(s) |
D0QH9W |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013010963 |
| Title |
Use of Coumarin Derivatives for The Preparation of Drugs for Treating Skin Diseases. |
| Abstract |
The invention relates to a compound of formula (I-1) wherein n equals 0 or 1, Z represents O or S, R1 represents one group chosen among the group consisting ofhydrogen, C1-C7 alkyl, substituted, or not, by a halogen, a hydroxyl or a O-R12 group, wherein R12 is a C1-C7 alkyl, a group CH2OCOR5 wherein R5 is chosen among a hydrogen atom and a C1-C7 alkyl, substituted or not by at least one halogen, a group O-R13, wherein R13 is chosen among hydrogen and a C1-C7 alkyl, an amine or a CH2-amine, R1 represents a group chosen among hydrogen and O-R14, wherein R14 is chosen among hydrogen and a C1-C7 alkyl, and R2 is chosen among the group consisting of a C1-C7 alkyl, a C3-C6 cycloalkyl, an aryl group, and an heteroaryl group for its use for the treatment of pathologies involving an excess of activity of at least one member of the kallikrein family. |
| Applicant(s) |
Universite Pierre et Marie Curie (Paris 6) |
| Representative Drug(s) |
D02MGJ |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012083385 |
| Title |
Serine Protease Inhibitors. |
| Abstract |
The invention relates to KLK protease inhibitors. In particular, the invention is directed to KLK14, KLK7 and/or KLK5 protease inhibitors and their uses in the diagnosis, prevention or treatment of a skin disease or pathology, or other undesirable skin condition. |
| Applicant(s) |
Queensland University of Technology |
| Representative Drug(s) |
D02MGJ |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2017100679 |
| Title |
Plasma Kallikrein Inhibitors and Uses Thereof for Treating Hereditary Angioedema Attack. |
| Abstract |
Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in treating and preventing hereditary angioedema attack, such method may involve a first treatment period and optionally, a second treatment period. Also provided are methods of using such antibodies in treating hereditary angioedema involving a single dose of the antibody to a subject who has undergone a prior HAE treatment, followed by multiple doses of the same antibody if the subject experiences an HAE attack after the single dose. |
| Applicant(s) |
Dyax Corp |
| Patent ID |
WO2017059178 |
| Title |
Human Plasma Kallikrein Inhibitors. |
| Abstract |
Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity. |
| Applicant(s) |
Biocryst Pharmaceuticals, Inc |
| Patent ID |
WO2016083816 |
| Title |
N-((Heteroarylmethyl)-Heteroaryl-Carboxamide Derivatives As Plasma Kallikrein Inhibitors. |
| Abstract |
The present invention provides a selection of compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds. |
| Applicant(s) |
Kalvista Pharmaceuticals Limited |
| Patent ID |
WO2016044662 |
| Title |
Pyrazolyl-Substituted Pyridone Compounds As Serine Protease Inhibitors. |
| Abstract |
There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins. |
| Applicant(s) |
Verseon Corporation |
| Patent ID |
WO2015022547 |
| Title |
Bicyclic Inhibitors. |
| Abstract |
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein A, B, W, X and Y are as defined herein. |
| Applicant(s) |
Kalvista Pharmaceuticals Limited |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US9670157 |
| Title |
Benzylamine Derivatives. |
| Applicant(s) |
Kalvista Pharmaceuticals Limited |
| Representative Drug(s) |
D02YUQ |
Drug Info
|
IC50 = 1 to 2 nM |
Click to Show More |
[1] |
|
2
|
D0JO6Z
|
Drug Info
|
IC50 = 1 to 2 nM
|
[1] |
|
3
|
D0QH9W
|
Drug Info
|
N.A.
|
[1] |
| Patent ID |
US20170189470 |
| Title |
Peptide and Peptidomimetic Inhibitors. |
| Applicant(s) |
Ra Rharmaceuticals Inc |
| Representative Drug(s) |
D0QH9W |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US9533987 |
| Title |
Heterocyclic Derivates. |
| Applicant(s) |
Kalvista Pharmaceuticals Limited |
| Patent ID |
US9512065 |
| Title |
Polymorphs of N-[(R)-1-[(S)-1-(4-Aminomethyl-Benzylcarbamoyl)-2-Phenyl-Ethylcarbamoyl]-2-(4-Ethoxy-Phenyl)-Ethyl]-Benzamide Hydrochloride. |
| Applicant(s) |
Kalvista Pharmaceuticals Limited |
| Patent ID |
US9051249 |
| Title |
Benzylamine Derivatives As Inhibitors of Plasma Kallikrein. |
| Applicant(s) |
Kalvista Pharmaceuticals Limited |
| Patent ID |
US20170065570 |
| Title |
Multisubstituted Aromatic Compounds As Serine Protease Inhibitor. |
| Applicant(s) |
Verseon Corp |
| Patent ID |
US20170037003 |
| Title |
Therapeutic Compounds and Compositions. |
| Applicant(s) |
Exithera Pharmaceuticals Inc |
| Patent ID |
US20160222063 |
| Title |
Benzylamine Derivatives As Inhibitors of Plasma Kallikrein. |
| Applicant(s) |
Bicycle Therapeutics Limited |
| Patent ID |
US20120328517 |
| Title |
Kallikrein-Binding Kunitz Domain Proteins and Analogs Thereof. |
| Applicant(s) |
Dyax Corp |
| China National Intellectual Property Administration (CNIPA) |
| Patent ID |
CN105330665 |
| Title |
Kallikrein Klk7 Inhibiting Compound and Preparation Method and Application Thereof. |
| Applicant(s) |
Hengyang Normal University |
